Holen Sie sich die Stockscreener-App
2.96
1.00%
-0.03
Handel nachbörslich:
3.00
0.04
+1.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-04-05 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect - accessnewswire.com
Anavex Life Sciences Corp. (AVXL) stock price, news, quote and history - Yahoo Finance UK
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect | NDAQ:AVXL | Press Release - stockhouse.com
3 Promising Penny Stocks With At Least $200M Market Cap - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Sciences Corp (12X1.HM) Recent Insider Transactions - ca.finance.yahoo.com
AVXL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Anavex Life Sciences' (AVXL) Buy Rating Reaffirmed at D. Boral Capital - marketbeat.com
Anavex Life Sciences Provides Comprehensive Regulatory Update - The Manila Times
After withdrawing its EU filing, Anavex keeps Alzheimer’s drug in talks - stocktitan.net
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Stockholders to Connect - ACCESS Newswire
Anavex Life Sciences stock crushed as European Alzheimer's drug filing pulled after EMA pushback - MSN
2026-03-27 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Anavex Life Sciences Under Investigation for Securities Fraud - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - PR Newswire
Vanguard reports 0 AVXL shares after internal realignment (AVXL) - Stock Titan
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Sahm
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip? - Yahoo Finance
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation - Yahoo Finance
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist - Bitget
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback - TradingView
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine - Stock Titan
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results - StocksToTrade
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease - Bitget
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union. - Bitget
Anavex Life Sciences provides update on regulatory review in the EU for blarcamesine to treat early Alzheimer's disease - marketscreener.com
Anavex Life Sciences stock tumbles after EU filing withdrawal By Investing.com - Investing.com Australia
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences stock tumbles after EU filing withdrawal - Investing.com
EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan
Anavex Life lead drug targets early Alzheimer's causenew study highlights - MSN
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage - Stocktwits
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease - The Manila Times
Study ties oral Alzheimer’s drug to slower brain shrinkage - Stock Titan
Anavex Life Lead Drug Targets Early Alzheimer's CauseNew Study Highlights - Sahm
Form 8K Anavex Life Sciences Corp For: 9 February - Investing.com
Anavex Life Sciences Announces New Study Linking Autophagy Dysfunction to Alzheimer’s Disease Pathology - Quiver Quantitative
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease - The Manila Times
Alzheimer’s study points to cell-cleanup failure before plaques form - Stock Titan
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):